AKT1 and neoplasm: For example in the IPATential150 study, men with mCRPC with PTEN-loss tumours had improved rPFS on treatment with abiraterone and an AKT inhibitor versus abiraterone alone (18.5 months vs 16.5 months, p = 0.034) [32].